Research

Grant Opportunity for Novel, High-Risk IBD-Related Research

Wednesday, 11 January 2017 15:32

The Kenneth Rainin Foundation encourages scientists worldwide to pursue unconventional ideas outside the boundaries of mainstream Inflammatory Bowel Disease (IBD) research. If you have a novel idea, you should apply for a $100,000 Innovator Award to support a one-year proof-of-concept research project that could potentially lead to transformative discoveries about IBD. This award program is open to researchers in any scientific discipline, and from any nonprofit research institution worldwide. Learn more about eligibility, budget guidelines and how to apply. Letters of inquiry will be accepted online from January 15 - February 15, 2017.

forCrohn's Innovation Grant 2017

Monday, 09 January 2017 12:08

Background

forCrohn's is the UK's only charity solely dedicated to Crohn’s disease. Their mission is to fund research that helps those with the condition today and contributes to finding a cure for Crohn's disease in the future whilst making more people in the UK aware of the disease and its symptoms. They fund £80,000-100,000 basic science and clinical research annually in various specialist institutions.

Aim of the Innovation Grant

The aim is to support gastroenterology healthcare professionals to find new ways to immediately improve the lives of patients with Crohn's disease.

Funding

forCrohn's new innovation grant will be used to fund projects that demonstrate a clear and immediate benefit for Crohn's disease patients. Up to £10,000 will be awarded to successful applicants. The application process is open from 1 January 2017 - 13 March 2017.

Criteria of grant

All projects must meet the following criteria and will be judged against them:

  • An outcome which demonstrates a clear and immediate benefit for Crohn's patients
  • (Whilst it is appreciated that many projects may have a dual benefit for those with UC, the charity's main aim is focused on the output for Crohn's)
  • A short expected time between study and implementation
  • Robust assessment of outcomes
  • Potential to scale nationally for pilot projects

For more information about the Innovation Grant and to download an application form, please go to http://bit.ly/forcrohnsinnovation

 

HTA 16/166 & 16/167 - Researcher-led open calls

Friday, 16 December 2016 16:05

HTA 16/167 (researcher-led, expression of interest to full) and HTA 16/166 (researcher-led, evidence synthesis full proposal) have been advertised. The application deadline for both calls is 1pm on 5 April 2017. Information and guidance are available on the NIHR website.

NIHR PGFAR - Competition 23

Monday, 28 November 2016 17:05

Programme Grants aim to produce independent research findings that will have practical application for the benefit of patients and the NHS in the relatively near future. Programme Development Grants are a complementary scheme to allow investigators to undertake preparatory research that will position them to submit a competitive Programme Grant application. The deadline for submission of Stage 1 applications is 1pm 29 March 2017. Research funded through a Programme Grant typically consists of an interrelated group of high quality projects focused on a coherent theme. The projects will therefore require multidisciplinary approaches, including clinical, health economics, statistics, qualitative and behavioural sciences, to ensure that research objectives can be met. The amount awarded and the length of the funding period will depend on the nature of the proposed work, in particular whether or not the proposal includes a substantial powered trial. Programme Grants will now launch three Competitions per year, with Stage 1 opening for applications in February, June and October. Please see the call schedule on the PGFAR Calls and Competitions page for further details.

State-of-the-Art Workshop on Measurement Reactivity

Monday, 28 November 2016 13:37

The MRC/NIHR Methodology Research Programme Advisory Group has called for applications to lead an MRC-NIHR methodology workshop on measurement reactivity. Understanding measurement reactivity (an individual’s behavioural, emotional and psychological change as a result of being measured) in medical/healthcare research contexts is a key area of uncertainty. The workshop would inform the writing and publication of a framework/guidance paper or state-of-the-art report, led by the organising group. The finished document will be reviewed by MRC/NIHR for approval before publication. A budget of up to £50,000 is available; the application deadline is 4pm GMT on 28 Feb 2017.

NIHR HTA 16/162 - Low-dose antidepressants for the treatment of irritable bowel syndrome

Monday, 28 November 2016 12:55

There is some evidence for the clinical effectiveness of low-dose antidepressants in treating the symptoms of IBS. However, this comes from studies based primarily within secondary or tertiary care settings with low participation rates. There is uncertainty about whether these drugs are effective for people with IBS seen in primary care. Most people with IBS are treated in this setting, and may be different in a number of respects to those seen in secondary and tertiary care. Therefore, research on the relative short- and long-term benefits of low-dose TCAs and/or SSRIs in primary care populations would help guide treatment decisions. The Health Technology Assessment Programme therefore seeks to answer "What is the clinical and cost effectiveness of low-dose TCAs and/or SSRIs for the treatment of irritable bowel syndrome (IBS) in primary care?" Details of the commissioning call are available from the NIHR website, along with the guidance notes. The deadline for applications is 1pm on 6 April 2017.

NIHR HTA 16/152 - Selective gut decontamination in critically ill children

Monday, 28 November 2016 12:45

In order to answer the research question "Is it feasible to conduct a study of selective gut decontamination in critically ill children in paediatric intensive care?", the Health Technology Assessment (HTA) programme is commissioning research into whether selective gut decontamination through oropharyngeal and gastric application of specific non-absorbable antibiotics to reduce/eradicate the presence of harmful microorganisms only, as opposed to using broad spectrum antibiotics that can disrupt the gut’s natural flora, can directly or indirectly reduce morbidity and mortality in children admitted to paediatric intensive care units. There is the risk of antibiotic resistance developing. Therefore, the Paediatric Intensive Care Society has highlighted that this is an important area for further research before such a strategy can be recommended. Given that this intervention is not currently used in UK PICUs, a feasibility and randomised pilot trial is proposed in the first instance to determine whether it will be possible to deliver a substantive trial. Potential applicants are also directed to the guidance notes. Applications are due by 1pm on 6 April 2017.

NIHR HTA 16/142 - The role of bile duct imaging in gallbladder surgery

Monday, 28 November 2016 12:39

The Health Technology Assessment (HTA) Programme seeks to answer the following research question: "What is the cost effectiveness of routine common bile duct imaging in patients planned for cholecystectomy at low to medium risk of common bile duct stones?" Failure to detect gallstones within the biliary tree may result in the leakage of bile from the cystic duct, or jaundice and infection after surgery. Detecting these stones may minimise potential morbidity and allows the treatment of the stones prior to, during, or after gallbladder surgery. Preoperative and intraoperative imaging procedures (such as magnetic resonance cholangiopancreatography (MRCP) and intraoperative cholangiography (IOC)) can identify asymptomatic common bile duct stones that can then be removed. What is unclear is which method is optimal for the imaging of potential common bile duct stones and whether routine imaging for these stones has a role in patients undergoing gallbladder removal. NICE recommend that there is a clear need for “large, high quality trials to address clinical questions about the benefits and harms of IOC”, but experts feel that research needs to also look at other imaging methods. Full details of the commissioned call can be found on the NIHR website, along with guidance notes for potential applicants. The deadline for applications is 1pm on 9 February 2017.

NIHR HTA 16/141 - Proton pump inhibitor therapy for refractory gastro-oesophageal reflux symptoms

Monday, 28 November 2016 12:32

The Health Technology Assessment (HTA) Programme seeks an answer to the following research question: "Should patients who have persistent gastro-oesophageal reflux symptoms, despite first line therapy with a proton pump inhibitor (PPIs), move to a double/twice daily dose of PPI?" Gastro-oesophageal reflux (GOR) is a common condition with up to 1 in 10 people experiencing symptoms on a daily basis. It can affect people of all ages but is more common with advancing age. Symptoms of GOR arise when the valve mechanism between the stomach and oesophagus fails allowing acid from the stomach to leak into the oesophagus. Common symptoms include heartburn, acid reflux into the mouth, difficulty with and pain when swallowing.

First line treatment for GOR symptoms is usually a course of proton pump inhibitors (PPIs) but some estimates suggest up to 60% of patients fail to respond adequately. Despite little evidence, guidance recommends a doubling of PPI dose (to twice rather than once daily) or a switch of PPI, but such treatment of refractory reflux symptoms is only effective in 25% of patients. It has been suggested that those responding inadequately to PPIs probably do not have GOR and require additional investigations but PPI treatment remains commonplace. An adequately powered, efficiently designed and rigorously controlled randomised trial will provide the missing evidence as to whether refractory reflux symptoms should indeed be treated as guidance currently advocates or if first line PPI failure itself should signpost to further investigation and perhaps a different treatment pathway. Details of the funding call and the associated guidance are available on the NIHR website. The deadline for applications is 1pm on 9 February 2017.

NIHR HTA 16/94 - Gastric residual volume measurement in mechanically ventilated infants and children

Monday, 28 November 2016 12:22

The Health Technology Assessment (HTA) Programme seeks an answer to the following research question: "Is it feasible to conduct a study identifying the impact of not measuring gastric residual volume on clinical outcomes in mechanically ventilated infants and children receiving enteral feeding?" Mechanically ventilated children on neonatal and paediatric intensive care units are fed directly into their stomachs via a tube (enteral feeding) to ensure that they are provided with the necessary nutrition to sustain organ and body system functions and aid their recovery. Enteral feeding is vital but some children do not tolerate feeding well and it is thought that this can increase the risk of food being regurgitated and entering the lungs (pulmonary aspiration) which can lead to ventilator-associated pneumonia (VAP).

One proposed way of measuring ‘tolerance’ to the feeds, which is current standard practice in intensive care units, is to measure the volume of gastric contents at periodic intervals (GRV or “gastric residuals”). To measure GRV, enteral feeds are stopped for a period of time while the gastric contents are sucked out and measured. It is believed that if there is a ‘high’ volume of food in the stomach then this indicates poor tolerance and potential gastrointestinal dysfunction which could increase the risk of VAP and associated morbidities. However, the value of periodic GRV measurements with regard to risk reduction of VAP incidence has frequently been questioned in recent years as there is very limited evidence for this theoretical risk. Surveys suggest that there is no standard “acceptable” GRV at which to stop enteral feeds. Furthermore, this practice contributes to the underfeeding of children admitted to NICU or PICU who already achieve poor calorie delivery, which could have a knock-on effect on their recovery. Measuring GRV is also a very time-intensive process for nurses to undertake particularly when there is little evidence to support its use.

Two large randomised clinical trials in adults revealed that abandoning GRV monitoring did not negatively affect clinical outcomes (including VAP) in mechanically ventilated patients. However, there is currently no evidence to suggest that this could be translated to neonatal and paediatric intensive care settings. Given that all UK NICUs and PICUs currently measure GRV, the HTA programme is interested in commissioning, in the first instance, one study combining both NICU and PICU settings to determine whether future randomised controlled trial/s in these population groups would be feasible to do.Guidance notes are available for potential applicants; the deadline is 1pm on 7 February 2017.

NIHR HTA 16/89 - Interventions for small bowel Crohn's disease

Monday, 28 November 2016 12:14

The deadline for applications for this commissioned funding call is 1pm on 7 February 2017. The Health Technology Assessment (HTA) Programme aims to answer the following research question: "What is the effectiveness of various bowel-conserving interventions for managing small bowel strictures in Crohn’s disease?" Crohn's disease may cause the intestine to develop strictures causing narrowing of the bowel. Strictures are often resected, although some surgeons may aim to preserve the bowel. Shorter strictures may be treated by bowel sparing interventions such as strictureplasty or endoscopic balloon dilatation. However, the long-term efficacy of these interventions has been questioned: in the case of balloon dilatation, many patients require more dilatations or post-dilatation surgery. There is no strong evidence to suggest which is the best bowel-conserving treatment option, and there appears to be no consensus in the surgical community about management strategies for this patient group. Hence, a study is suggested to identify likely front running approaches to manage the disease, such as recommended by the IDEAL framework stage 2B. A decision on whether to advertise for a substantive trial will be made in light of the results of research funded by this call. Guidance is available for potential applicants.

NIHR EME 16/126 - Researcher-led funding call

Monday, 28 November 2016 12:01

The NIHR Efficacy and Mechanisms Evaluation (EME) programme welcomes researcher-led applications that meet the programme remit. Projects must have a strong collaborative approach, involving at least two of academia, NHS and industry. The EME Programme is particularly keen to encourage collaboration with small and medium enterprises. The EME Programme welcomes studies adopting novel and efficient study designs or that include the development or testing of new methodologies in an embedded methodological study (EMS).

The EME Programme funds ambitious studies evaluating interventions that have the potential to make a step-change in the promotion of health, treatment of disease and improvement of rehabilitation or long-term care. Within these studies EME supports research to improve the understanding of the mechanisms of both diseases and treatments. The programme supports translational research evaluating a wide range of novel or re-purposed interventions. The interventions may include diagnostic or prognostic tests and decision-making tools, drugs or biological compounds, psychological treatments, medical devices, and public health initiatives delivered within the NHS.

Full details of the call are available from the NIHR website, along with guidance notes. The application deadline is 1pm on 14 March 2017.

NIHR EME 16/128 - Improving Safety and Efficacy Through Targeted Drug Delivery

Monday, 28 November 2016 11:35

The Efficacy and Mechanism Evaluation (EME) Programme is seeking applications for research to improve treatment outcomes through the use of targeted drug delivery techniques. Techniques of particular interest include i) nanocarriers such as liposomes, microspheres and emulsions ii) externally applied energy forms and iii) highly specific viral vectors, including oncolytic therapies, but other novel targeting techniques are welcome. Applications may investigate novel or repurposed drugs using targeting technologies.

Applications must concentrate on determining the clinical efficacy of interventions using targeted drug delivery. The inclusion of embedded hypothesis-driven mechanistic studies within the main clinical evaluation is strongly encouraged. Projects must have a strong collaborative approach, involving at least two of academia, NHS and industry. The EME Programme is particularly keen to encourage collaboration with small and medium enterprises.

Full details of the commissioned call are available on the NIHR website, along with a guidance document. The application deadline is 1pm on 14 March 2017.

Kenneth Rainin Foundation Funding Calendar

Friday, 25 November 2016 15:01

The Rainin Foundation believes that providing early support for innovative ideas can lead to improvements in preventing, diagnosing and treating Inflammatory Bowel Disease. Find out more about the Foundation and view their grant awards calendar.

Graham Bull prize in clinical science and Goulstonian Lectureship 2017

Wednesday, 23 November 2016 13:07

The Graham Bull prize was established in 1988 in honour of Sir Graham Bull, who was the first director of the Clinical Research Centre at Northwick Park. A trust for the Graham Bull prize was set up to provide money for young research workers under the age of 45 who feel that they have made a major contribution to clinical science.

The prize as designed by the trust is specifically for an application and not for nomination of individuals. The work can cover a wide range of expertise, such as:

  • molecular and cellular biology
  • imaging technology
  • psychiatry
  • health sciences

The award is open to RCP members and fellows who must apply for their own work to be considered. The sum of £1,000 is offered on a competitive basis each year.

The winner of this prize will be invited to deliver the Goulstonian Lecture, an annual lecture endowed in 1635 by Mrs Ellen Goulston in memory of her husband, Dr Theodore Goulston FRCP.

Researchers must be under the age of 45 on the application closing date (as per the terms of the original bequest), and must be a member or fellow of RCP London.

Further information, including details of how to apply, may be found on the RCP website:

Deadline for applications: Friday 31st March 2017

The Core-Dr Falk Pharma UK Awards 2017

Monday, 31 October 2016 13:28

To celebrate 10 years of collaboration, promoting research and investing in young researchers, Core and Dr Falk are pleased to announce the 2017 awards. In addition to the awards below, a new award for specialist gastroenterology/hepatology registrars will be announced early in 2017.

The Core - Dr Falk awards recognise the achievements of those who bring new knowledge and insight to the field of gastroenterology and hepatology. For those committed to furthering research or patient care, these awards provide an opportunity to achieve national recognition as well as the financial support for career progression.

Awards include:

  • A £1,000 prize for the best essay on gastroenterology or hepatology research personally undertaken by medical students who were on an intercalated BSc/MRes/MBPhD/MSc/MPH course during the previous academic year (2015/16)
  • Four £1,500 prizes for medical students taking full-time science degrees (BSc/MRes/MBPhD/MSc/MPH) focusing on gastrointestinal or liver-related disease in the current academic year (2016/17)
  • Two £2,500 awards for F1/F2 doctors to facilitate prospective research in an area relevant to gastroenterology or hepatology
  • A £1,000 award for primary and secondary care gastrointestinal / liver nurses for initiatives that have advanced patient care.

The application deadline is 5.00pm on Friday 3rd March 2017. Applications received after this time will not be considered.

For further information and to apply:

NIHR Public Health Research Programme 16/121 - Healthy diet in early years

Monday, 17 October 2016 09:04

Background to commissioning brief

Healthy dietary intake during the early years of life supports children to grow and develop physiologically and psychologically towards a healthy life, and is important in preventing and reducing obesity, as highlighted in the recently published government Childhood Obesity plan for action.

Interventions which promote breastfeeding and that improve weaning and dietary quality in early years can reduce the risk of over-nutrition and chronic diseases in later life. Interventions designed to promote healthy diet and good nutrition in early childhood need to understand and address the factors influencing and determining children’s diets.

Establishing healthy weaning practices and developing eating habits may cause concern for parents, with little information on the best approaches, and addressing problems. However, despite the increasing number of interventions and public health importance, results continue to be inconsistent and there is a lack of well - designed studies evaluating interventions for healthy diets in early years. Population level interventions are of interest.

Deadline: 1pm, 25 April 2017

Further Information

Additional Documents

NIHR HTA 16/89 - Interventions for small bowel Crohn's disease

Tuesday, 02 August 2016 11:05

Research Question:

What is the effectiveness of various bowel-conserving interventions for managing small bowel strictures in Crohn’s disease?

Intervention: Management strategies for small bowel strictures in Crohn's disease, such as endoscopic small-bowel balloon dilatation, small-bowel strictureplasty, etc.

Patient group: Adults with small bowel Crohn’s disease and short strictures which are potentially amenable to bowel sparing interventions, such as stricturoplasty or balloon dilatation. Applicants to define.

Setting: Secondary care.

Study design: A prospective cohort study and consensus process working with clinicians and patients to identify likely front running approaches to manage this disease, such as recommended by IDEAL framework stage 2B. Study to incorporate a prospective data collection including information on learning curves, patient views on why they have made a particular treatment decision and a systematic literature review. Applicants should consider how this would lead onto further primary research.

Outcomes: Disease-specific quality of life measure; recurrence of symptomatic strictures, reoperation rate; recommendations for future research. A decision on whether to advertise for a substantive trial will be made in light of the results of this study.

NHS decision problem to be addressed by this research:

Crohn's disease is a chronic inflammatory disorder that can affect any part of the gastrointestinal tract from the mouth to the anus, but most commonly causes inflammation and ulceration of the ileum and the colon. It may cause the intestine to develop strictures causing narrowing of the bowel.

Strictures are often resected, although some surgeons may aim to preserve the bowel. Shorter strictures may be treated by bowel sparing interventions such as strictureplasty or endoscopic balloon dilatation. However, the long-term efficacy of these interventions has been questioned: in the case of balloon dilatation, many patients require more dilatations or post-dilatation surgery. There is no strong evidence to suggest which is the best bowel-conserving treatment option, and there appears to be no consensus in the surgical community about management strategies for this patient group. Hence, a study is suggested to identify likely front running approaches to manage the disease, such as recommended by the IDEAL framework stage 2B.

Deadline: 1pm, 7 February 2017

Further Information

NIHR HTA 16/94 - Gastric residual volume measurement in mechanically ventilated infants and children

Tuesday, 02 August 2016 10:43

Research Question:

Is it feasible to conduct a study identifying the impact of not measuring gastric residual volume on clinical outcomes in mechanically ventilated infants and children receiving enteral feeding?

Intervention: No measurement of gastric residual volume (GRV) alongside standard care (to be manualised as part of this commission).

Patient group: Infants and children expected to receive a prolonged period of mechanical ventilation with enteral feeding, to be defined by applicants.

Setting: Neonatal intensive care units (NICU) and Paediatric intensive care units (PICU).

Control: Usual care, ie periodic measuring of GRV as part of standard care (to be manualised as part of this commission).

Study design: A stand-alone feasibility study to 1) Manualise standardised GRV testing and treatment regimen/s to be used as the control arm of a future trial/s as well as appropriate protocol/s to be used in the intervention arm that would ensure clinically significant differences in calorie delivery and 2) Determine whether substantive randomised controlled trial/s of the intervention would be possible in these populations and settings. A randomised element is not expected as part of this commission.

Important outputs: Manualised intervention and control regimens (which may depend on age and setting); determination of equipoise among clinicians; patient eligibility and exclusion criteria; important outcomes to be measured in a trial; willingness to implement intervention; indication of whether a randomised controlled trial/s would be feasible. A decision on whether to advertise for one or more substantive trial/s in one or both of these populations will be made in light of the results of this feasibility study.

NHS decision problem to be addressed by this research:

Mechanically ventilated children on neonatal and paediatric intensive care units are fed directly into their stomachs via a tube (enteral feeding) to ensure that they are provided with the necessary nutrition to sustain organ and body system functions and aid their recovery. Enteral feeding is vital but some children do not tolerate feeding well and it is thought that this can increase the risk of food being regurgitated and entering the lungs (pulmonary aspiration) which can lead to ventilator-associated pneumonia (VAP).

 

One proposed way of measuring ‘tolerance’ to the feeds, which is current standard practice in intensive care units, is to measure the volume of gastric contents at periodic intervals – the socalled GRV or “gastric residuals”. To measure GRV, enteral feeds are stopped for a period of time while the gastric contents are sucked out and measured. It is believed that if there is a ‘high’ volume of food in the stomach then this indicates poor tolerance and potential gastrointestinal dysfunction which could increase the risk of VAP and associated morbidities. However, the value of periodic GRV measurements with regard to risk reduction of VAP incidence has frequently been questioned in recent years as there is very limited evidence for this theoretical risk. Surveys suggest that there is no standard “acceptable” GRV at which to stop enteral feeds. Furthermore, this practice contributes to the underfeeding of children admitted to NICU or PICU who already achieve poor calorie delivery, which could have a knock-on effect on their recovery. Measuring GRV is also a very time-intensive process for nurses to undertake particularly when there is little evidence to support its use.

Two large randomised clinical trials in adults revealed that abandoning GRV monitoring did not negatively affect clinical outcomes (including VAP) in mechanically ventilated patients. However, there is currently no evidence to suggest that this could be translated to neonatal and paediatric intensive care settings. Given that all UK NICUs and PICUs currently measure GRV, the HTA programme is interested in commissioning, in the first instance, one study combining both NICU and PICU settings to determine whether future randomised controlled trial/s in these population groups would be feasible to do.

Deadline: 1pm, 7 February 2017

Further Information

 

 

NIHR HTA 16/99 - Primary prevention of variceal bleeding in patients with liver cirrhosis

Tuesday, 02 August 2016 09:54

NHS decision problem to be addressed by this research:

There is an increase in prevalence of cirrhosis in the UK. Bleeding from oesophageal varices is a major complication of liver cirrhosis and a major cause of mortality. Approximately half of those with cirrhosis have oesophageal varices and one-third of all persons with varices will develop variceal haemorrhage at some point. The 6-week mortality associated with variceal bleeding remains around 10–20%.

National and international guidelines on liver cirrhosis recommend that all patients with liver cirrhosis be offered surveillance for oesophageal varices and that those with medium/large varices (>5mm) are offered primary prophylactic therapy with NSBB.

The 2015 British Society of Gastroenterology UK guidelines on the management of variceal haemorrhage in cirrhotic patients[3] recommend non-cardioselective β blockers (NSBB) or VBL with pharmacological treatment with propranolol as first line and, VBL offered if there are contraindications to NSBB. The choice of VBL or NSBB should also take into account patient choice.

The lack of good quality trials in this area has been highlighted again in 2016 in a recent BMJ publication by Li et al, Carvedilol for portal hypertension in cirrhosis: systematic review with metaanalysis.

Research Question:

What is the clinical and cost effectiveness of non-selective beta-blockers compared to endoscopic variceal band ligation for primary prevention of variceal bleeding?

Intervention: Oral non-selective beta-blockers (NSBB), choice to be justified by applicants.

Patient group: Adults with cirrhosis and medium or large oesophageal varices, no history of variceal haemorrhage and no contraindications to beta blocker use.

Setting: Secondary care.

Control: Endoscopic variceal band ligation (VBL).

Study design: A randomised non inferiority trial to compare NSBB against VBL. When appropriate subgroup analyses should be performed. The trial data should also be incorporated into a new or updated systematic review with meta-analyses. A model of cost effectiveness is required.

Important outcomes: Time to first variceal bleeding event; overall mortality. Other outcomes: Adverse effects; an updated meta-analysis; patient preference; QoL; cost effectiveness.

Minimum duration of follow-up: Duration of study sufficient to accumulate enough events to inform the model.

Deadline: 1pm, 7 February 2017.

Further Information

The aim of the HTA Programme is to ensure that high quality research information on the effectiveness, costs and broader impact of health technology is produced in the most efficient way for those who use, manage, provide care in or develop policy for the NHS. Topics for research are identified and prioritised to meet the needs of the NHS. Health technology assessment forms a substantial portfolio of work within the National Institute for Health Research and each year about fifty new studies are commissioned to help answer questions of direct importance to the NHS. The studies include both primary research and evidence synthesis.

 

HTA researcher-led funding opportunities

Tuesday, 02 August 2016 09:01

The researcher-led workstream welcomes proposals on topics or research questions identified by researchers within the programme’s remit. The HTA can verify this for you if you complete and submit a remit check form. The deadlines for the next rounds are Wednesday 30 November 2016, Wednesday 5 April 2017, Wednesday 9 August 2017, Tuesday 5 December 2017. Details can be found on the HTA website.

2016 NIHR Clinical Lectureships (Medical)

Friday, 29 July 2016 11:28

The 2016 NIHR Clinical Lectureships (medical) opened on 1st March 2016 and will close on 31st March 2017.

NIHR Clinical Lectureships (CLs) are specialty training posts that incorporate academic training. NIHR Clinical Lecturers (CLs) spend 50% of their time undertaking specialist clinical training and 50% undertaking research or educational research training.

CLs are aimed at those who are advanced in their specialty training, have completed a research doctorate or equivalent and show outstanding potential for continuing a career in academic medicine. The duration of a CL is for a maximum of 4 years and it is expected that CLs will complete their specialty training during this period. Alongside clinical training, CLs will be able to further develop their academic skills and will be encouraged to apply for funding to support further Post-Doctoral or educational research training.

There are currently two gastroenterology posts open, which you can view on the list below. The first is in Yorkshire & Humber, Sheffield the second in Wessex, Southampton.

List of open posts

Further Information

You may also be interested in:

The Kenneth Rainin Foundation - Innovator Awards

Tuesday, 26 July 2016 15:26

The Kenneth Rainin Foundation supports research that is potentially transformative to diagnosing, treating and curing Inflammatory Bowel Disease. The Innovator Awards program provides $100,000 grants for one-year research projects, which due to their ground-breaking nature, may not be suitable for funding from more traditional sources. To date, they have funded projects in the following areas:

  • Bioengineering
  • Diet and Nutrition
  • Epithelial Cell/Molecular Biology
  • Fecal Microbiota Transplant
  • Immunity and Inflammation
  • Microbiome
  • Therapeutic Development and Delivery

If you are submitting a clinical research proposal, they encourage you to include basic scientific methodologies to examine the underlying mechanisms of the proposed intervention/treatment.

Funding criteria include:

  • Innovation
  • Scientific merit
  • Strong evidence of collaboration
  • Investigator capability to execute project

Researchers from any scientific discipline at non-profit research institutions worldwide are eligible for funding. Typically, the researchers they fund hold advanced degrees (MD, PhD or the equivalent) and academic positions at universities, medical centers or research institutions. Innovator Awards may have only one principal investigator, and funding is awarded to their home institution; however, additional investigators may be listed as co-investigators.

Letter of Inquiry Deadline: January 15 – February 15, annually

Further Information

The Haemochromatosis Society Grants

Thursday, 21 July 2016 08:22

The Society works with the scientific community to support research into genetic haemochromatosis, and provides grants to tackle basic scientific, treatment or social issues that affect patients with haemochromatosis.

Grant proposals are accepted at any time from researchers working in recognised institutions in the UK. Suitable applications progress to peer-review and a decision as to whether to fund a project is made at the earliest possible quarterly board meeting.

Projects that may improve the rates of diagnosis and lower the average age of diagnosis of genetic haemochromatosis are welcome.

Scientific research into iron overload and its treatment is ongoing worldwide. The society has a small research budget, which the trustees apply after consulting our scientific advisers, to support research in the UK.

Further Information

The Society for Surgery of the Alimentary Tract (SSAT) Career Development Award

Friday, 17 June 2016 10:19

This award for young faculty members is to assist in the establishment of investigators, basic or clinical, in digestive diseases.

Eligibility Criteria

  • The supported research program can be focused on basic laboratory or rigorous clinical investigation.
  • The award is restricted to surgeons who have completed formal clinical and research training in general surgery and are within five years of their first faculty appointment in a department of surgery at a medical school accredited by the Liaison Committee on Medical Education in the United States or by the Committee for Accreditation of Canadian Medical Schools in Canada, or the equivalent national accrediting body for applicants from other countries.
  • A significant amount of time should be devoted to research to accomplish the investigator's goals. The Head of Department and Division of General Surgery must ensure that the applicant has the required protected time for research.
  • The SSAT award of $50,000USD per year for two years is a career development award and is meant to support young investigators who have not been funded by a National Institutes of Health R01 Award. In addition, if an investigator has received a similar type career development award from another organization such as the American College of Surgeons, American Surgical Association Foundation, etc., he/she will be ineligible for the SSAT Career Development Award. This is the applicant's responsibility to notify the SSAT of potential funding conflicts.
  • The award is not to diminish or replace the customary, expected compensation or benefits; nor is any portion of the award to be used for institutional indirect costs.
  • The recipient will present a progress report to the SSAT Annual Meeting during and immediately following the period of award.
  • It is expected that the recipient submit any abstracts deriving from his/her Career Development Award-funded research to the SSAT Annual Meeting for presentation consideration, as well as any manuscripts to the Journal of Gastrointestinal Surgery, the official journal of the SSAT, for publication consideration.

Further Information

The deadline for the 2017 award is January 13, 2017.

AGA-Moti L. & Kamla Rustgi International Travel Awards

Wednesday, 25 May 2016 10:01

Total Award Amount: 750USD
Eligible Categories: DDW Travel Award, Travel Award
This award provides 750USD to two young basic, translational or clinical investigators residing outside North America to support their travel and related expenses to attend Digestive Disease Week® (DDW).

Objective
- To enable young investigators outside of North American institutions to attend DDW and encourage them to maintain a commitment to digestive disease research.

Eligibility Criteria
- Candidates for this award must hold an MD or PhD degree or a non-US equivalent degree (e.g. MB, ChB, MBBS, DO), be 35 years of age or younger at the time of DDW and be fluent in English.

- AGA membership is required at the time of application submission. The applicant must be sponsored by an international AGA member. Please visit the membership page or call 301-654-2055, extension 651, for membership information.

- Applicants must be the first author of an abstract accepted by the AGA for presentation at DDW and provide evidence of abstract acceptance.

- Applicants may only submit one abstract for consideration.

Deadline: 24th February 2017

Further Information

American Gastroenterological Association (AGA) Student Abstract Prize

Wednesday, 25 May 2016 00:00

Total Award Amount: Up to 1,000USD

Eligible Categories: DDW Travel Award, Student Award, Travel Award
Travel awards will be given to high school, undergraduate, graduate and medical students who have submitted abstracts chosen by AGA to be presented during Digestive Disease Week® (DDW). Medical residents, up to and including postgraduate year three, are also eligible for the award.

Objective
The overall objective of this award is to stimulate interest in gastroenterology/hepatology research careers through competition and recognition.

Eligibility
- Candidates for this award must be a high school, undergraduate, graduate or medical student or medical resident (up to and including postgraduate year three) who has performed original research related to diseases, structure or functioning of the digestive system.

- Post doctoral fellows, technicians, visiting scientists and MD research fellows are not eligible for this award.

- Applicants may only submit one abstract for consideration and must be the designated presenter or first author of the abstract.

- The applicant’s sponsor must be an AGA member at the time of application submission.

- Women and minority students are strongly encouraged to apply.


Deadline: 24th February 2017

Further Information

The American Society of Colon and Rectal Surgeons (ASCRS) Limited Project Grant (LPG)

Tuesday, 24 May 2016 10:24

Purpose

To provide the investigator with the opportunity to pursue research interests, specifically germane to the field of colon and rectal surgery. It is anticipated that successful research projects, initially funded through the Research Foundation’s LPG mechanism, will ultimately secure funding from other national funding agencies.

Amount
Up to 50,000USD/year
Application Deadlines: March 1st and October 1st
Review/Notification Date: Summer/Fall (March applicants) or Winter/Spring (October applicants)

Further Information / Apply

Health Education England (HEE) and NIHR Webinar

Thursday, 05 May 2016 08:40

HEE and NIHR hosted a webinar providing an overview of its Integrated Clinical Academic (ICA) Programme but also useful hints and tips for applying.

It is a useful resource for those applying for Round 2 competitions for Clinical Doctoral Research Fellowships and Clinical Lectureships and Senior Clinical Lectureships.

You’ll need to register first before watching the webinar.

MRC Supporting new researchers towards independence

Thursday, 28 April 2016 14:09

To support early career researchers the MRC has increased the flexibility of its funding schemes available to post-doc researchers along with providing clearer guidance. Recognising that speed of progression can be affected by factors unrelated to an individual’s scientific potential, the MRC have removed time-bound eligibility criteria from New Investigator Research Grants.

Further Guidance

MRC Regenerative Medicine Research - New Funding Approach

Thursday, 28 April 2016 13:56

MRC has recently made some changes to the way regenerative medicine research is funded.

The Regenerative Medicine Research Committee will now focus funding into Confidence in Concept projects, spreading its £2m allocation over ten or so projects.

Further Guidance

MRC Flexible Funding

Thursday, 28 April 2016 13:31

MRC fellowships are open to individuals returning to research following a career break.

Applicants should make clear any substantive periods of absence from research within their application. Details of career breaks or flexible working will only be used to make appropriate adjustments when assessing an individual’s track record, productivity and career progression.

Further Details

NIHR Invention for Innovation Programme - 12th call for Product Development Awards

Tuesday, 12 April 2016 11:15

Invention for Innovation (i4i) is a translational funding scheme to advance healthcare technologies and interventions for increased patient benefit in areas of existing or emerging clinical need. Similarly, the Health Innovation Challenge Fund (HIC Fund), a partnership between the Department of Health and the Wellcome Trust, is also a translational funding scheme and complements the NIHR i4i Programme at a key translational gap.

i4i supports collaborative research and development projects that have demonstrated proof-of-principle and have a clear pathway towards adoption and commercialisation. The expected output is an advanced or clinically validated prototype medical device, technology or intervention. The aim is to de-risk projects and make them attractive to follow-on funders and investors.

There are two funding streams, Product Development awards and Challenge awards, which comprise early to late stage product development, including first-in-man and clinical feasibility studies and pivotal clinical studies to evaluate the safety and effectiveness for the intended use. The ultimate aim is to get products or services to a position where they can enter and be used within the NHS.

National Cancer Research Institute (NCRI) Advisory Group

Friday, 08 April 2016 15:25

The NCRI Advisory Groups offer specialist advice and peer review for trial proposals or ideas in the areas of Molecular Biomarkers, Imaging, and Screening Prevention & Early Diagnosis (SPED). The Advisory Groups are 'open for business' and encourage you to get in touch with your trial ideas.

Find out more here.

CLDF Small Grants Programme

Friday, 08 April 2016 13:28

The trustees of Children’s Liver Disease Foundation (CLDF) will make available £20,000 per annum for a small grants research programme. Applications must be in line with CLDF's research strategy. The money will be distributed quarterly with a maximum of £5,000 being awarded in any one quarter. Applicants may apply for up to £5,000 in a quarter. Successful applicants will not be eligible to apply for a further year following an award being made. The trustees will look favourably on applications where the candidates can show that they can add value to the contribution made by CLDF. Those who can show matching funding from their institution or other sources will be regarded favourably. The next funding round is 1 October – 31 December followed by 1 January – 31 March. Please find information on applying for a CLDF Small Grant here.

Broad Medical Research Program at CCFA (BMRP-CCFA)

Friday, 08 April 2016 13:03

Crohn’s & Colitis Foundation of America recognises the importance of conducting innovative research that will lead to improvements in the prevention, diagnosis or therapy of Crohn’s disease or ulcerative colitis. CCFA funds innovative, clinically relevant research projects that will have the potential to impact the lives of patients with inflammatory bowel diseases. If you have an idea for an exploratory pilot research project, please consider applying for a grant from BMRP-CCFA. This is an investigator- friendly process with a three page Letter of Interest with a rolling deadline open to any nationality and rapid turnaround for decisions. BMRP-CCFA aims to help persons with inflammatory bowel diseases (IBD) by stimulating innovative, early stage research that opens new avenues for the diagnosis, therapy and prevention of these diseases. BMRP-CCFA is a great mechanism to fund innovative ideas that are clinically relevant and can lead to rapid change in the care of patients with inflammatory bowel diseases. Interested parties can find further information about the program and the projects it seeks to fund.

NIHR Research Design Service

Friday, 08 April 2016 12:58

The NIHR Research Design Service (RDS) network helps researchers prepare proposals for submission to NIHR and other national, peer-reviewed funding competitions for applied health or social care research, by providing expert advice on research design and methodology. RDS advisers in bases across England offer a unique breadth of experience and a proven track record in improving research applications. Advice is confidential and free of charge. For more information, visit the Research Design Service website.

New research funding announced by MRC 15 February 2016

Thursday, 07 April 2016 15:46

The Medical Research Council (MRC) is accelerating innovative medical research with £23.2 million in new funding to take ground-breaking ideas from UK universities into industry and out to patients.

The Crohn's in Childhood Research Association Bursaries

Thursday, 07 April 2016 15:22

Bursary grants of up to £400 (up to a total amount of £5,000pa) to enable UK based young doctors still in training/nurses/final year medical students and similar persons with an interest in the area of Crohn's and colitis (IBD) to support attendance at national, international scientific/educational congresses and if considered appropriate IBD related training courses. Also a £1000 annual bursary for travel/registration at national and international meetings for doctors in training to become paediatric gastroenterologists.

Application forms and further information can be obtained from the CICRA website: http://www.cicra.org/what-we-do/research/grant-applications

MRC Biochemical Catalyst: Developmental Pathway Funding Scheme

Thursday, 07 April 2016 15:20

The DPFS scheme is a key part of the MRC's Translational Research Strategy and supports the translation of fundamental discoveries toward benefits to human health. It funds the pre-clinical development and early clinical testing of novel therapeutics, devices and diagnostics, including “repurposing” of existing therapies. DPFS is an ongoing scheme, with outline deadlines every 4 months. The next three deadlines for outline proposals are 4pm on 29th March 2017, 26 July 2017 and 29 November 2017. Further details, including the deadlines for the next three calls, can be found on the submission deadlines page for the scheme.

Please note that full submissions to DPFS are by invitation only; submission to the full call is contingent upon prior submission and shortlisting of an outline proposal. Further details are available from the MRC website.

Pump prime funding for initial feasibility studies

Thursday, 07 April 2016 15:17

NIHR Enteric HTC aims to identify and address unmet clinical need in the diagnosis and management of disorders of the gastrointestinal tract and bowel function. The HTC seeks new ideas for medical device innovations and offers the opportunity to apply to NIHR Enteric HTC for pump prime funding for initial feasibility studies on potential new medical technologies within the field of digestive diseases and GI surgery.